- Cancer Research Institute. FDA approves new immunotherapy for metastatic melanoma 2011. http://www.cancerresearch.org/news/2011/fda-approves-new-immunotherapy-for-melanoma. Accessed April 20, 2024.
- Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–2376. doi:10.1056/NEJMoa2201445.
- Saowapa S, Polpichai N, Siladech P, et al. Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2024;37(4):613–622. doi:10.1080/08998280.2024.2342723.
- Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update [published correction appears. J Clin Oncol. 2021;39(36):4073–4126. doi:10.1200/JCO.21.01440.
- Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother. 2007;30(1):130. doi:10.1097/01.cji.0000211334.06762.89.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
- Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi:10.1056/NEJMoa1414428.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 4
Reviews
Adding insult to injury: immunotherapy-induced colitis in metastatic colorectal cancer
Katerina WellsDepartment of Surgery, Baylor University Medical Center, Dallas, Texas, USACorrespondence[email protected]
https://orcid.org/0000-0002-4699-2178
, MD, MPHhttps://orcid.org/0000-0002-4699-2178